Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scilex Holding Company filings document the regulatory record for an operating biopharmaceutical company with Nasdaq-listed common stock and warrants. Its disclosures cover material-event reports, material agreements, capital-structure matters, security-holder rights, clinical or regulatory updates, operating and financial results and risk-related information connected to its non-opioid pain management products and development activities.
Scilex proxy materials address annual meeting votes, director elections, auditor ratification and amendments to the company’s equity incentive plan. Other filings include Regulation FD and 8-K disclosures, preferred-stock and warrant-related security structure matters, legal-proceeding disclosures and reporting-status items such as notifications tied to annual-report timing and financial-statement preparation.
Scilex Holding Co. reported a grant of an incentive stock option to Stephen Ma, who serves as CFO, COO and a director. The option, dated 10/08/2025, covers 60,000 shares of common stock with an exercise price of $17.58. Vesting occurs monthly at 1/48th of the option each month following the grant, subject to continued service.
The option cannot be exercised until the issuer's outstanding indebtedness under a Senior Secured Promissory Note to Oramed Pharmaceuticals and the Tranche B Senior Secured Convertible Notes to several holders has been repaid in full. The option shows an exercisable date of 10/08/2035 and the reporting person beneficially owns 60,000 shares subject to the option.
Director Chun Jay received a grant of a nonstatutory stock option to purchase 20,000 shares of common stock with an exercise price of $17.58. The option was granted on 10/08/2025, vests at 1/48th per month following the grant subject to continued service, and expires on 10/08/2035. The filing was reported on Form 4 by an attorney-in-fact on 10/09/2025. The option is held directly and the reported exercise price for the underlying shares is shown as $0 in the table for the resulting common stock record (the derivative itself lists $17.58 as the conversion/exercise price).
Insider option grant and vesting conditions. The CEO and President, Ji Henry, received an incentive stock option to buy 120,000 shares of Scilex Holding Co common stock at $17.58 per share on 10/08/2025. The option vests monthly at a rate of 1/48th of the shares following the grant, subject to continued service, and expires on 10/08/2035. The option cannot be exercised until the company’s outstanding indebtedness under a Senior Secured Promissory Note and certain Tranche B Senior Secured Convertible Notes has been repaid in full. The filing was signed by an attorney‑in‑fact on 10/09/2025.
Reporting person: Followwill Dorman, a director of Scilex Holding Co (SCLX), received a nonstatutory stock option grant. The option gives the right to buy 20,000 shares of common stock at an exercise price of $17.58 per share. The grant date and transaction date are 10/08/2025 and the option expires on 10/08/2035.
The option vests monthly at a rate of 1/48 of the total shares subject to the option, conditioned on the reporting persons continued service. After the grant, the reporting person directly beneficially owns 20,000 shares subject to the option. The form was signed by an attorney-in-fact on 10/09/2025.
Scilex Holding Company reported a leadership change, appointing Stephen Ma as Chief Operating Officer, effective October 1, 2025. Ma, age 53, has been the Company’s Chief Financial Officer and Senior Vice President since September 2023 and Corporate Secretary since March 2024, and he joined the board of directors in September 2025.
His background includes more than 15 years of finance and operational experience at multiple pharmaceutical and biotechnology companies, including prior roles at Semnur Pharmaceuticals, Anwita Biosciences, Semnur Inc., Globavir, Ardelyx, PDL BioPharma and Hyperion Therapeutics. Scilex states there are no family relationships or related-party transactions requiring disclosure, no special arrangements for his selection, and his compensation remains unchanged in connection with his appointment as Chief Operating Officer.
Scilex Holding Company entered into a Securities Purchase Agreement with Datavault AI Inc. under which Datavault will issue 15.0 million shares of its common stock and a pre-funded warrant to buy 263,914,094 additional shares for an aggregate purchase price of $150 million.
On September 26, 2025, Datavault issued the initial 15.0 million shares to Scilex at a per share price of $0.5378, paid in Bitcoin based on the Coinbase.com spot rate the prior trading day. After Datavault obtains required stockholder approval, including an increase in authorized common stock up to 1.5 billion shares, it will issue Scilex a pre-funded warrant for 263,914,094 shares with an exercise price of $0.0001 per share in exchange for approximately $141.9 million.
The warrant will be immediately exercisable upon issuance, carry anti-dilution adjustments for stock splits and dividends, and entitle Scilex to participate in rights offerings and dividends as if the warrant were exercised. The Datavault securities are being offered under Datavault’s effective shelf registration statement on Form S-3.
Scilex Holding Company and Scilex, Inc. filed a Schedule 13D reporting combined beneficial ownership of 188,554,849 shares of Semnur Pharmaceuticals, Inc. common stock, representing 79.89% of the outstanding common shares (based on 236,021,088 shares outstanding as of September 25, 2025). Including 5,423,606 shares of Series A Preferred Stock held by SHC (voting on an as-converted basis), the reporting persons control 80.34% of the issuer's total voting power.
The filing explains the ownership arose from a business combination completed September 22, 2025, related debt-equity exchanges (SHC contributed $54,236,058 of outstanding indebtedness in exchange for 5,423,606 preferred shares and received 542,361 common shares), conversion of a $124,883.82 convertible note into 12,488 common shares, and other transactions. The filing also discloses a resale of 12,500,000 shares to Biconomy at $16.00 per share payable in Bitcoin and contract rights giving SHC director designation rights and veto-like protections over certain corporate actions.
Scilex Holding Company entered into a Securities Purchase Agreement with Biconomy PTE.LTD to sell 12,500,000 shares of Semnur Pharmaceuticals common stock, a majority-owned subsidiary, at $16.00 per share, with the purchase price payable in Bitcoin based on a Coinbase spot rate. The shares consist of 554,849 Semnur shares held by Scilex Holding Company and 11,945,151 shares held by Scilex, Inc., and the transaction closed on September 25, 2025. Under the agreement, Semnur must file a registration statement within 90 days to register Biconomy’s resale of these shares. The company also furnished a press release about the deal and filed supplemental risk factor disclosures to update prior public filings.
Scilex Holding Company reported board changes tied to a previously announced business combination involving its subsidiary Semnur Pharmaceuticals and Denali Capital Acquisition Corp. Directors Annu Navani and Jaisim Shah resigned on September 22, 2025, and the company stated their resignations were not due to disagreements over operations, policies or practices.
At the same time, Scilex entered into a Consulting Agreement with Inform LLC, an entity affiliated with Mr. Shah. Inform LLC will provide consulting services for five years for a $50,000 monthly fee. Following the resignations, the board size decreased from six to five directors, and Chief Financial Officer and Senior Vice President Stephen Ma was appointed to fill the resulting vacancy. The company noted Mr. Ma has no family relationships with other leaders and no related party transactions requiring disclosure.
Scilex Holding Co. and related reporting persons disclosed multiple dispositions of Semnur Pharmaceuticals, Inc. (SMNR) common stock executed under a Securities Purchase Agreement. The filing reports dispositions on 09/23/2025: a sale of 11,945,151 shares at a reported price of $16, an additional sale of 554,849 shares at $16, and indirect ownership reported of 6,250,000 shares by Scilex Bio, Inc. The filing shows an aggregate indirect beneficial ownership figure of 181,804,849 shares following one reported transaction. The purchase price for the transactions was stated to have been paid in Bitcoin based on the Coinbase spot rate at 8:00 p.m. New York time on the trading day before closing.